IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

NANOPARTICLE-BASED DRUG DELIVERY SYSTEMS FOR TARGETED TREATMENT OF BREAST CANCER

Eshita Kar Mandal
Assistant Professor, Department of Chemistry,
Sevayatan Sikshan Mahavidyalaya,
Sevayatan- 721514, Jhargram,W.B., India

Abstract: Breast cancer is among the most prevalent cancers affecting women worldwide, accounting for a significant proportion of cancer-related morbidity and mortality. Conventional therapies, such as chemotherapy and radiation, have made strides in improving survival rates; however, their limitations including poor specificity, systemic toxicity, and the emergence of drug resistance highlight the need for alternative treatment modalities. Nanoparticle-based drug delivery systems (NDDS) have emerged as a groundbreaking approach, leveraging their nanoscale size, biocompatibility, and multifunctionality to enhance therapeutic targeting and reduce adverse effects. This article delves into the advancements, challenges, and future prospects of NDDS for the targeted treatment of breast cancer, examining diverse nanoparticle types, their surface modification techniques, and their potential in clinical settings.

Keywords - Nanoparticles, targeted drug delivery, breast cancer treatment.

1. INTRODUCTION

Breast cancer remains a leading cause of cancer-related mortality in women, with over 2 million new cases reported annually. While advancements in medical science have provided a range of treatment options, including surgery, chemotherapy, radiation therapy, and hormonal therapy, these modalities often lack the precision necessary to distinguish between cancerous and healthy tissues. This lack of specificity can lead to severe off-target effects, including damage to vital organs, and significantly diminishes patients' quality of life. Furthermore, issues such as multidrug resistance and tumor recurrence pose additional challenges to successful treatment (Akram et al., 2017; Barrios, 2022; Giaquinto et al., 2022; Loibl et al., 2024; Łukasiewicz et al., 2021; Mehrotra & Yadav, 2022).

Nanotechnology has introduced revolutionary changes in oncology, offering innovative tools for early diagnosis, imaging, and drug delivery. Nanoparticles, with their unique physicochemical properties, such as their ability to traverse biological barriers, high drug-loading capacity, and customizable surface chemistry, represent a paradigm shift in cancer therapy. These properties enable targeted drug delivery systems that improve therapeutic efficacy while reducing systemic toxicity, thereby addressing some of the critical shortcomings of conventional treatments. This paper explores the potential of nanoparticle-based systems to transform breast cancer therapy, offering insights into their mechanisms, applications, and future directions (Alrushaid et al., 2023; Al-Thani et al., 2024; Chehelgerdi et al., 2023; Karahmet Sher et al., 2024; Kemp & Kwon, 2021; Sim & Wong, 2021).

2. NANOPARTICLES FOR DRUG DELIVERY

Nanoparticles are small-scale materials (1-100 nm) with high surface-area-to-volume ratios, tunable surface chemistry, and versatile functionalization potential. Their ability to encapsulate therapeutic agents ensures protection from premature degradation, controlled release, and enhanced bioavailability (Chehelgerdi et al., 2023; Lan et al., 2023; Patra et al., 2018). Key nanoparticle types used in breast cancer therapy include:

2.1. LIPOSOMES

Liposomes are phospholipid bilayer vesicles capable of encapsulating both hydrophilic and hydrophobic drugs. This dual-encapsulation ability ensures compatibility with a wide range of therapeutic agents, including small molecules, peptides, and nucleic acids. By modifying their surface with polyethylene glycol (PEG), liposomes achieve prolonged circulation time in the bloodstream, evading detection by the immune system (Y. Jiang et al., 2023; Nsairat et al., 2022; Tenchov et al., 2021). Pegylated liposomal formulations, such as Doxil®, have demonstrated significant clinical benefits, including enhanced tumor accumulation via the enhanced permeability and retention (EPR) effect and reduced cardiotoxicity, making them particularly effective in treating breast cancer. Additionally, liposomes can be functionalized with ligands, such as antibodies or peptides, for active targeting to breast cancer cells, further improving their specificity and therapeutic potential (Aloss & Hamar, 2023; Brown & Khan, 2012; J. Chen et al., 2024; Pandey et al., 2016; Taher et al., 2023).

2.2. POLYMERIC NANOPARTICLES

These are synthesized using biocompatible polymers like PLGA (poly(lactic-co-glycolic acid)) and PEG (polyethylene glycol). Polymeric nanoparticles enable controlled drug release through mechanisms such as diffusion, polymer degradation, or a combination of both. This controlled release can be fine-tuned to achieve sustained drug levels at the tumor site, reducing the need for frequent dosing and enhancing patient compliance. Additionally, their surfaces can be modified with various functional groups, targeting ligands, or stealth coatings to evade immune detection and improve tumor-specific accumulation. Recent advances include polymeric nanoparticles loaded with combination therapies, such as chemotherapeutic agents and immunomodulators, which synergistically enhance therapeutic outcomes for breast cancer treatment (Begines et al., 2020; Calzoni et al., 2019; Elmowafy et al., 2023; Makadia & Siegel, 2011; R. Sun et al., 2024).

2.3. METAL-BASED NANOPARTICLES

Gold and magnetic nanoparticles offer diverse diagnostic and therapeutic applications, including photothermal therapy (PTT), magnetic hyperthermia, and drug delivery. Gold nanoparticles (AuNPs), owing to their strong surface plasmon resonance, can convert light energy into heat, effectively destroying cancer cells during PTT. Magnetic nanoparticles, such as iron oxide, are utilized in magnetic hyperthermia, where an alternating magnetic field generates localized heat to kill tumor cells. Furthermore, these nanoparticles can be functionalized with targeting ligands, such as antibodies or peptides, to improve their specificity for breast cancer cells. Their ability to serve as contrast agents in imaging techniques, like MRI or CT scans, enhances their theranostic potential, combining therapy and diagnostics in a single platform. This multifunctionality underscores their growing significance in breast cancer treatment (Amaral et al., 2024; Hu et al., 2020; Riley & Day, 2017; Sakore et al., 2024; Sibuyi et al., 2021; Vines et al., 2019).

2.4. DENDRIMERS

Dendrimers are highly branched, tree-like polymers characterized by their unique architecture, which provides a large number of surface functional groups and internal cavities. These properties enable high drug-loading capacities and the ability to encapsulate both hydrophilic and hydrophobic drugs. Their surface can be easily functionalized with targeting ligands such as antibodies, peptides, or small molecules to achieve specific targeting of breast cancer cells. Furthermore, dendrimers exhibit precise molecular weight and structure, which allows for controlled and predictable drug release. Recent studies have highlighted their potential for delivering not only chemotherapeutic agents but also genes, siRNA, and imaging agents, making them versatile tools in breast cancer therapy (Choudhary et al., 2017; Jain et al., 2020; Jayaswal et al., 2024; Mittal et al., 2021; Núñez et al., 2016; Santos et al., 2019; Zhang et al., 2014).

2.5. CARBON-BASED NANOMATERIALS

Carbon nanotubes (CNTs) and graphene oxide (GO) have garnered significant attention for their drug delivery potential, attributed to their exceptional mechanical strength, thermal stability, and high surface area. CNTs, with their hollow tubular structure, provide ample space for drug encapsulation and efficient transport across biological barriers. They can also be functionalized with targeting moieties to enhance specificity toward breast cancer cells. Similarly, GO's large surface area and abundance of functional groups make it an excellent platform for loading multiple therapeutic agents, including drugs, genes, and imaging probes. Furthermore, both CNTs and GO exhibit unique optical and electrical properties, enabling their use in photothermal and photodynamic therapies, where localized heat or reactive oxygen species generation is used to destroy cancer cells. Despite their promise, challenges related to biocompatibility, potential toxicity, and safe clearance from

the body must be addressed for their successful clinical application (Arora & Attri, 2020; Debnath & Srivastava, 2021; Jha et al., 2020; Rathinavel et al., 2021; Shar et al., 2023; Sharma, 2024).

3. Targeting Strategies

Efficient targeting of breast cancer cells is a cornerstone of NDDS development, ensuring that therapeutic agents reach the tumor site with high precision while sparing healthy tissues. Several approaches have been developed to achieve this goal, targeting of breast cancer cells is crucial for the success of NDDS (Luo et al., 2023; Priyadarshni et al., 2024; Reddy Baddam et al., 2024; Surya et al., 2024). Common targeting strategies include:

3.1. Passive Targeting

Passive targeting leverages the enhanced permeability and retention (EPR) effect, a phenomenon observed in tumor tissues due to their abnormal vascular architecture and poor lymphatic drainage. These structural abnormalities allow nanoparticles to extravasate and accumulate preferentially in the tumor microenvironment. The EPR effect is particularly advantageous for delivering nanoparticles loaded with chemotherapeutic agents, as it minimizes systemic distribution and associated side effects. However, the effectiveness of passive targeting can vary depending on factors such as tumor type, size, and location, as well as the physicochemical properties of the nanoparticles, including size, surface charge, and hydrophilicity (Acharya & Sahoo, 2011; Bazak et al., 2014; L. Chen et al., 2018; Stylianopoulos, 2013; Subhan et al., 2021; Wu, 2021).

3.2. Active Targeting

Active targeting involves the use of ligands, such as antibodies, peptides, or aptamers, that are designed to bind specifically to receptors overexpressed on the surface of breast cancer cells, such as HER2, EGFR, or folate receptors. By attaching these ligands to the surface of nanoparticles, it is possible to achieve precise interaction with cancer cells while avoiding normal tissues. For instance, trastuzumab-functionalized nanoparticles have shown remarkable specificity for HER2-positive breast cancer cells, enhancing therapeutic efficacy (Bazak et al., 2015; Fraguas-Sánchez et al., 2022; Salahpour Anarjan, 2019). Similarly, folate-functionalized nanoparticles exploit the high affinity of folate for its receptor, which is frequently overexpressed in breast cancer. This strategy not only improves drug accumulation in the tumor microenvironment but also enhances cellular uptake through receptor-mediated endocytosis, leading to more effective drug delivery and reduced systemic toxicity (Bazak et al., 2015; Prajapati et al., 2024; Shi et al., 2023; Yan et al., 2024).

3.3. Stimuli-Responsive Systems

Stimuli-responsive nanoparticles are engineered to release therapeutic agents in response to specific environmental triggers, such as pH, temperature, redox conditions, or enzymatic activity, ensuring precise drug delivery to the tumor site. For instance, the acidic microenvironment of tumors (pH ~6.5) compared to normal tissues (pH ~7.4) can trigger pH-sensitive nanoparticles to release their payload selectively at the tumor site. Similarly, thermosensitive nanoparticles respond to elevated temperatures, which can be induced locally using external heat sources, to enable controlled drug release. Enzyme-responsive nanoparticles utilize enzymes overexpressed in tumor tissues, such as matrix metalloproteinases, to degrade specific bonds and release the drug. These systems enhance therapeutic efficacy by minimizing premature drug release and reducing off-target effects, while also offering opportunities for integrating imaging modalities for real-time monitoring of drug delivery (Bhattacharya et al., 2023; Li et al., 2019; Mi, 2020; Oshiro-Júnior et al., 2020; Thomas et al., 2020; Xin & Naficy, 2022; Zandieh et al., 2023; Zou et al., 2021).

4. Advantages of NDDS in Breast Cancer Therapy

Nanoparticle-based drug delivery systems (NDDS) offer transformative advantages for breast cancer therapy, addressing limitations of conventional treatment approaches. Key benefits include:

4.1. Enhanced Specificity and Reduced Toxicity

By targeting tumor-specific markers and utilizing the enhanced permeability and retention (EPR) effect, NDDS concentrate therapeutic agents precisely within the tumor microenvironment, minimizing exposure to healthy tissues. This specificity not only improves the therapeutic index but also significantly reduces systemic toxicity, which is a common drawback of conventional chemotherapies. By sparing healthy tissues, NDDS contribute to fewer side effects such as nausea, hair loss, and organ damage, ultimately enhancing the

overall quality of life for patients undergoing breast cancer treatment (Gao et al., 2024; Liu et al., 2023; Malik et al., 2023a; S. Sun et al., 2023; Zou et al., 2021).

4.2. Improved Drug Stability

Encapsulation within nanoparticles protects therapeutic agents from enzymatic degradation, oxidative damage, or hydrolysis in the bloodstream, thereby preserving their structural integrity and pharmacological activity. This protection extends the half-life of drugs, allowing them to remain active for a longer duration within the systemic circulation. Consequently, nanoparticles enhance bioavailability and ensure that a higher proportion of the therapeutic agent reaches the tumor site, maximizing efficacy and minimizing waste (Gao et al., 2024; Huang et al., 2024; L. Jiang et al., 2023; Kumari et al., 2014; Liu et al., 2023; Zou et al., 2021).

4.3. Controlled Release

NDDS enable precise control over drug release kinetics, tailoring the timing and location of therapeutic action to maximize efficacy. Stimuli-responsive designs, such as pH-sensitive systems, release drugs specifically in the acidic microenvironment of tumors, while temperature-sensitive nanoparticles can be activated by localized heating to ensure site-specific delivery. These features allow for a steady release of drugs, reducing the frequency of administration and ensuring sustained therapeutic levels at the tumor site. Such precise control minimizes drug wastage, enhances patient compliance, and reduces side effects associated with fluctuating drug levels in the body (Adepu & Ramakrishna, 2021; Chu et al., 2022; Huang et al., 2024; L. Jiang et al., 2023; Malik et al., 2023a; Mukherjee & Raikwar, 2024; S. Sun et al., 2023; Yap et al., 2021).

4.4. Multifunctionality

Beyond drug delivery, nanoparticles can be engineered for theranostic applications, seamlessly integrating therapeutic and diagnostic functions into a single platform. For instance, nanoparticles can deliver anticancer drugs while simultaneously serving as imaging agents, such as fluorescent markers, magnetic resonance imaging (MRI) contrast agents, or computed tomography (CT) enhancers, allowing for real-time monitoring of treatment efficacy. This dual functionality enables clinicians to track the distribution and accumulation of nanoparticles within the tumor, assess therapeutic response, and make timely adjustments to treatment regimens. Furthermore, theranostic nanoparticles hold promise in predicting therapeutic outcomes, offering insights into tumor heterogeneity and enabling personalized treatment strategies (Gao et al., 2024; Janib et al., 2010; L. Jiang et al., 2023; Liu et al., 2023; L. Sun et al., 2023; S. Sun et al., 2023).

These features highlight the potential of NDDS to overcome the challenges associated with traditional therapies, offering a more efficient and patient-centric approach to breast cancer treatment.

5. Challenges and Limitations

Nanoparticle-based drug delivery systems (NDDS) offer transformative potential in breast cancer therapy, but several challenges and limitations impede their widespread clinical application.

5.1. Biocompatibility and Toxicity

Despite the significant strides in designing nanoparticles for biocompatibility, challenges remain, particularly with certain materials such as metal-based nanoparticles. These materials can induce toxicity through mechanisms like oxidative stress, inflammation, or triggering of immune responses. For instance, prolonged exposure to gold nanoparticles has been associated with cytotoxic effects in some cellular studies, while iron oxide nanoparticles have shown potential to disrupt cellular homeostasis. Furthermore, the biodistribution and long-term safety of many nanomaterials remain incompletely characterized, raising concerns about their accumulation in non-target organs, such as the liver, spleen, or kidneys. This necessitates extensive in vivo and clinical evaluations to establish comprehensive safety profiles. To address these challenges, research is increasingly focusing on developing biodegradable and bioresorbable nanoparticles that naturally degrade into non-toxic byproducts. Such designs aim to minimize adverse effects and promote efficient clearance from the body, ensuring both safety and efficacy in therapeutic applications (Gavas et al., 2021; Mirza & Karim, 2021; Paris et al., 2019; Shafei et al., 2017).

5.2. Complex Manufacturing Processes

The synthesis of nanoparticles involves precise control over parameters such as size, shape, and surface modifications, which are critical for ensuring their therapeutic consistency and efficacy. Achieving these controls in a laboratory setting is already a meticulous process, but scaling them for mass production introduces additional layers of complexity. Maintaining uniformity and quality at a commercial scale requires advanced engineering solutions, highly specialized equipment, and strict adherence to quality control

protocols, all of which significantly increase production costs. Furthermore, variability in raw materials and the necessity for sterile production environments to meet regulatory standards add further challenges. Innovations in automated manufacturing systems, continuous processing techniques, and alternative scalable synthesis methods are being explored to address these issues and make NDDS more commercially viable (Abolhassani et al., 2024; Agrahari & Agrahari, 2018; Awasthi et al., 2018; Desai, 2012; Oehler et al., 2024).

5.3. Regulatory Hurdles

Nanoparticle-based therapies face stringent and often ambiguous regulatory frameworks. The novel nature of NDDS complicates the standardization of approval pathways, leading to prolonged timelines for clinical validation and commercialization. Harmonizing international regulatory standards and developing specific guidelines for nanomedicines are critical steps toward streamlining their clinical translation (Barua & Mitragotri, 2014; Desai, 2012; Oehler et al., 2024; Patel et al., 2024; Surya et al., 2024).

5.4. Tumor Heterogeneity

Breast cancer exhibits significant inter- and intra-tumor heterogeneity, including variations in genetic profiles, receptor expression, and microenvironmental factors. This variability can reduce the efficacy of NDDS by impairing targeting precision and drug delivery efficiency. Strategies to overcome this challenge include the design of nanoparticles capable of multiplexed targeting and the integration of real-time diagnostic tools to monitor therapeutic responses (Mirza & Karim, 2021; G. Song et al., 2014; X. Sun et al., 2022; Yu et al., 2022).

5.5. Drug Resistance Mechanisms

Tumors can develop resistance through mechanisms such as drug efflux, altered drug metabolism, and adaptive changes in the tumor microenvironment, which may limit the long-term effectiveness of NDDS. To address this, researchers are exploring combination therapies and co-delivery of agents that can inhibit resistance pathways alongside chemotherapeutic drugs (Duan et al., 2023; Gavas et al., 2021; Mirza & Karim, 2021; Ranji et al., 2015; Yao et al., 2020).

5.6. Cost and Accessibility

Advanced NDDS formulations often involve significant research, development, and production costs, driven by the need for sophisticated materials, complex synthesis methods, and stringent quality control protocols. These high costs can restrict accessibility in resource-limited settings, creating disparities in healthcare delivery. For example, the price of advanced nanoparticle therapies may exceed the budgets of public health systems in low- and middle-income countries, limiting their availability to a select group of patients. To address this challenge, researchers and policymakers are focusing on several strategies: simplifying nanoparticle designs to reduce production complexities, investing in scalable and cost-effective manufacturing techniques, and fostering public-private partnerships that subsidize development and distribution. These measures could help reduce costs, enhance affordability, and ensure broader adoption of these innovative treatments (Gavas et al., 2021; Mirza & Karim, 2021; Patel et al., 2024; Tang et al., 2017).

6. Clinical Applications and Progress

Several nanoparticle-based drug delivery systems (NDDS) have successfully transitioned from preclinical studies to clinical trials, reflecting their potential to revolutionize breast cancer therapy (Oehler et al., 2024; S. Sun et al., 2023). One notable example is albumin-bound paclitaxel (Abraxane®), a nanomedicine formulation that has demonstrated enhanced therapeutic efficacy and reduced systemic toxicity compared to conventional paclitaxel. By leveraging the albumin coating, this formulation facilitates improved tumor targeting via the enhanced permeability and retention (EPR) effect, leading to better clinical outcomes (Fang et al., 2015; Y. Jiang et al., 2022; Lei et al., 2022; Spada et al., 2021).

Ongoing clinical trials are investigating various advanced NDDS formulations designed to address specific challenges in breast cancer treatment. These include nanoparticles functionalized with monoclonal antibodies, such as trastuzumab, to target HER2-positive breast cancer cells. Additionally, NDDS incorporating immunotherapeutic agents, such as immune checkpoint inhibitors or tumor vaccines, are being explored to harness the immune system's ability to combat cancer (Gao et al., 2024; Malik et al., 2023b; Mukherjee & Raikwar, 2024; S. Sun et al., 2023).

Theranostic nanoparticles are also making strides in clinical research, combining therapeutic delivery with imaging capabilities for real-time monitoring of drug distribution and treatment response. For instance, iron oxide nanoparticles are being evaluated for their dual role in magnetic hyperthermia therapy and as contrast

agents in magnetic resonance imaging (MRI) (Baskaran et al., 2024; Oehler et al., 2024; Rashidi et al., 2024; Sneider et al., 2017).

Despite these advancements, the clinical translation of NDDS faces challenges such as regulatory hurdles, manufacturing scalability, and patient-specific variability. However, the growing body of evidence from clinical trials underscores the potential of these systems to improve therapeutic outcomes and pave the way for more effective, targeted, and personalized breast cancer treatments.

7. Future Perspectives

The future of nanoparticle-based drug delivery systems (NDDS) in breast cancer treatment lies in the convergence of advanced technologies, interdisciplinary research, and collaborative frameworks. One promising avenue is the integration of NDDS with artificial intelligence (AI). AI-driven algorithms can analyze vast datasets to identify optimal nanoparticle designs, predict patient-specific responses, and tailor treatment regimens for precision medicine. Such tools can also facilitate the discovery of novel biomarkers and aid in the development of nanoparticles with enhanced targeting efficiency (Cao et al., 2024; Oehler et al., 2024; Patel et al., 2024; S. Sun et al., 2023; Wasilewski et al., 2024).

Emerging gene-editing technologies, such as CRISPR-Cas9, are poised to further elevate the potential of NDDS. By incorporating CRISPR into nanoparticle platforms, researchers can enable precise gene-editing capabilities within cancer cells, targeting oncogenic mutations or restoring tumor-suppressor functions. This approach opens new avenues for personalized gene therapies in breast cancer treatment (Jia et al., 2024; Nie et al., 2022; Oehler et al., 2024; Padayachee & Singh, 2020; Z. Song et al., 2024).

Additionally, advancements in stimuli-responsive nanoparticles are expected to yield smarter drug delivery systems that respond to multiple triggers, such as pH, temperature, and enzymatic activity, simultaneously. These multi-responsive systems can improve drug release precision and offer real-time therapeutic adjustments, further enhancing efficacy (Al-Thani et al., 2024; Kaushik et al., 2022; Rahim et al., 2021).

Collaborative efforts between academia, industry, and regulatory agencies will play a pivotal role in overcoming existing challenges. Streamlining regulatory pathways, investing in scalable manufacturing processes, and promoting equitable access will be critical to the successful translation of NDDS into widespread clinical practice. Furthermore, continued research into biocompatibility and long-term safety will solidify public and professional confidence in these technologies (Oehler et al., 2024; Patel et al., 2024; Tang et al., 2017).

With these advancements, NDDS have the potential to not only transform breast cancer therapy but also serve as a blueprint for tackling other malignancies, ushering in a new era of personalized and effective cancer treatments.

8. Conclusion

Nanoparticle-based drug delivery systems represent a transformative approach to breast cancer treatment, offering targeted, efficient, and less toxic alternatives to conventional therapies. These systems capitalize on the unique physicochemical properties of nanoparticles to enhance the delivery, stability, and efficacy of therapeutic agents, minimizing systemic toxicity and improving patient outcomes. While challenges such as manufacturing scalability, biocompatibility, and regulatory approval remain significant, ongoing advancements in material science, artificial intelligence integration, and interdisciplinary collaboration continue to drive the field forward. As research progresses, NDDS are expected to revolutionize not only breast cancer therapy but also the broader landscape of oncology, paving the way for precision medicine and more accessible treatment modalities globally.

Acknowledgement

The author is grateful to her Ph.D. guide Prof. Syed Sirajul Islam, former Professor, Department of Chemistry and Chemical Technology, Vidyasagar University, West Bengal, for his continuous encouragement and constructive suggestions. The author is also grateful to her Institute for providing necessary research facilities.

Conflict of Interest

The author declares no conflict of interest.

REFERENCES

Abolhassani, H., Eskandari, A., Saremi Poor, A., Zarrabi, A., Khodadadi, B., Karimifard, S., Sahrayi, H., Bourbour, M., & Tavakkoli Yaraki, M. (2024). Nanobiotechnological approaches for breast cancer Management: Drug delivery systems and 3D In-Vitro models. *Coordination Chemistry Reviews*, *508*, 215754. https://doi.org/10.1016/j.ccr.2024.215754

Acharya, S., & Sahoo, S. K. (2011). PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. *Advanced Drug Delivery Reviews*, *63*(3), 170–183. https://doi.org/10.1016/j.addr.2010.10.008

Adepu, S., & Ramakrishna, S. (2021). Controlled Drug Delivery Systems: Current Status and Future Directions. *Molecules*, *26*(19), 5905. https://doi.org/10.3390/molecules26195905

Agrahari, V., & Agrahari, V. (2018). Facilitating the translation of nanomedicines to a clinical product: Challenges and opportunities. *Drug Discovery Today*, *23*(5), 974–991. https://doi.org/10.1016/j.drudis.2018.01.047

Akram, M., Iqbal, M., Daniyal, M., & Khan, A. U. (2017). Awareness and current knowledge of breast cancer. *Biological Research*, *50*(1), 33. https://doi.org/10.1186/s40659-017-0140-9

Aloss, K., & Hamar, P. (2023). Recent Preclinical and Clinical Progress in Liposomal Doxorubicin. *Pharmaceutics*, *15*(3), 893. https://doi.org/10.3390/pharmaceutics15030893

Alrushaid, N., Khan, F. A., Al-Suhaimi, E. A., & Elaissari, A. (2023). Nanotechnology in Cancer Diagnosis and Treatment. *Pharmaceutics*, *15*(3), 1025. https://doi.org/10.3390/pharmaceutics15031025

Al-Thani, A. N., Jan, A. G., Abbas, M., Geetha, M., & Sadasivuni, K. K. (2024). Nanoparticles in cancer theragnostic and drug delivery: A comprehensive review. *Life Sciences*, *352*, 122899. https://doi.org/10.1016/j.lfs.2024.122899

Amaral, M. N., Nunes, D., Fortunato, E., Martins, R., Rodrigues, C., Faísca, P., Ferreira, H. A., Coelho, J. M. P., Gaspar, M. M., & Reis, C. P. (2024). Gold nanoparticles for photothermal therapy – Influence of experimental conditions on the properties of resulting AuNPs. *Journal of Drug Delivery Science and Technology*, *101*, 106215. https://doi.org/10.1016/j.jddst.2024.106215

Arora, B., & Attri, P. (2020). Carbon Nanotubes (CNTs): A Potential Nanomaterial for Water Purification. *Journal of Composites Science*, *4*(3), 135. https://doi.org/10.3390/jcs4030135

Awasthi, R., Roseblade, A., Hansbro, P. M., Rathbone, M. J., Dua, K., & Bebawy, M. (2018). Nanoparticles in Cancer Treatment: Opportunities and Obstacles. *Current Drug Targets*, *19*(14), 1696–1709. https://doi.org/10.2174/1389450119666180326122831

Barrios, C. H. (2022). Global challenges in breast cancer detection and treatment. *The Breast*, *62*, S3–S6. https://doi.org/10.1016/j.breast.2022.02.003

Barua, S., & Mitragotri, S. (2014). Challenges associated with penetration of nanoparticles across cell and tissue barriers: A review of current status and future prospects. *Nano Today*, *9*(2), 223–243. https://doi.org/10.1016/j.nantod.2014.04.008

Baskaran, S., Siew, Q. Y., Tan, M. T. T., & Loh, H.-S. (2024). Theranostic tools against lung and breast cancers: Through the lens of mature gold nanoparticles and emerging graphene. *RPS Pharmacy and Pharmacology Reports*, *3*(1), rqae003. https://doi.org/10.1093/rpsppr/rqae003

Bazak, R., Houri, M., Achy, S. E., Hussein, W., & Refaat, T. (2014). Passive targeting of nanoparticles to cancer: A comprehensive review of the literature. *Molecular and Clinical Oncology*, *2*(6), 904–908. https://doi.org/10.3892/mco.2014.356

Bazak, R., Houri, M., El Achy, S., Kamel, S., & Refaat, T. (2015). Cancer active targeting by nanoparticles: A comprehensive review of literature. *Journal of Cancer Research and Clinical Oncology*, *141*(5), 769–784. https://doi.org/10.1007/s00432-014-1767-3

Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., & Alcudia, A. (2020). Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects. *Nanomaterials*, *10*(7), 1403. https://doi.org/10.3390/nano10071403

Bhattacharya, S., Prajapati, B. G., & Singh, S. (2023). A critical review on the dissemination of PH and stimuli-responsive polymeric nanoparticular systems to improve drug delivery in cancer therapy. *Critical Reviews in Oncology/Hematology*, *185*, 103961. https://doi.org/10.1016/j.critrevonc.2023.103961

Brown, S., & Khan, D. R. (2012). The Treatment of Breast Cancer Using Liposome Technology. *Journal of Drug Delivery*, *2012*, 1–6. https://doi.org/10.1155/2012/212965

Calzoni, E., Cesaretti, A., Polchi, A., Di Michele, A., Tancini, B., & Emiliani, C. (2019). Biocompatible Polymer Nanoparticles for Drug Delivery Applications in Cancer and Neurodegenerative Disorder Therapies. *Journal of Functional Biomaterials*, *10*(1), 4. https://doi.org/10.3390/jfb10010004

Cao, S., Wei, Y., Yue, Y., Wang, D., Yang, J., Xiong, A., & Zeng, H. (2024). Mapping the evolution and research landscape of ferroptosis-targeted nanomedicine: Insights from a scientometric analysis. *Frontiers in Pharmacology*, *15*, 1477938. https://doi.org/10.3389/fphar.2024.1477938

Chehelgerdi, M., Chehelgerdi, M., Allela, O. Q. B., Pecho, R. D. C., Jayasankar, N., Rao, D. P., Thamaraikani, T., Vasanthan, M., Viktor, P., Lakshmaiya, N., Saadh, M. J., Amajd, A., Abo-Zaid, M. A., Castillo-Acobo, R. Y., Ismail, A. H., Amin, A. H., & Akhavan-Sigari, R. (2023). Progressing nanotechnology to improve targeted cancer treatment: Overcoming hurdles in its clinical implementation. *Molecular Cancer*, *22*(1), 169. https://doi.org/10.1186/s12943-023-01865-0

Chen, J., Hu, S., Sun, M., Shi, J., Zhang, H., Yu, H., & Yang, Z. (2024). Recent advances and clinical translation of liposomal delivery systems in cancer therapy. *European Journal of Pharmaceutical Sciences*, *193*, 106688. https://doi.org/10.1016/j.ejps.2023.106688

Chen, L., Zang, F., Wu, H., Li, J., Xie, J., Ma, M., Gu, N., & Zhang, Y. (2018). Using PEGylated magnetic nanoparticles to describe the EPR effect in tumor for predicting therapeutic efficacy of micelle drugs. *Nanoscale*, *10*(4), 1788–1797. https://doi.org/10.1039/C7NR08319J

Choudhary, S., Gupta, L., Rani, S., Dave, K., & Gupta, U. (2017). Impact of Dendrimers on Solubility of Hydrophobic Drug Molecules. *Frontiers in Pharmacology*, *8*, 261. https://doi.org/10.3389/fphar.2017.00261

Chu, S., Shi, X., Tian, Y., & Gao, F. (2022). pH-Responsive Polymer Nanomaterials for Tumor Therapy. *Frontiers in Oncology*, *12*, 855019. https://doi.org/10.3389/fonc.2022.855019

Debnath, S. K., & Srivastava, R. (2021). Drug Delivery With Carbon-Based Nanomaterials as Versatile Nanocarriers: Progress and Prospects. *Frontiers in Nanotechnology*, *3*, 644564. https://doi.org/10.3389/fnano.2021.644564

Desai, N. (2012). Challenges in Development of Nanoparticle-Based Therapeutics. *The AAPS Journal*, *14*(2), 282–295. https://doi.org/10.1208/s12248-012-9339-4

Duan, C., Yu, M., Xu, J., Li, B.-Y., Zhao, Y., & Kankala, R. K. (2023). Overcoming Cancer Multi-drug Resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges. *Biomedicine & Pharmacotherapy*, *162*, 114643. https://doi.org/10.1016/j.biopha.2023.114643

Elmowafy, M., Shalaby, K., Elkomy, M. H., Alsaidan, O. A., Gomaa, H. A. M., Abdelgawad, M. A., & Mostafa, E. M. (2023). Polymeric Nanoparticles for Delivery of Natural Bioactive Agents: Recent Advances and Challenges. *Polymers*, *15*(5), 1123. https://doi.org/10.3390/polym15051123

Fang, R., Yang, S., Wang, Y., & Qian, H. (2015). Nanoscale Drug Delivery Systems: A Current Review on the Promising Paclitaxel Formulations for Future Cancer Therapy. *Nano*, *10*(05), 1530004. https://doi.org/10.1142/S1793292015300042

Fraguas-Sánchez, A. I., Lozza, I., & Torres-Suárez, A. I. (2022). Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinal Investigation to Clinic. *Cancers*, *14*(5), 1198. https://doi.org/10.3390/cancers14051198

Gao, L., Meng, F., Yang, Z., Lafuente-Merchan, M., Fernández, L. M., Cao, Y., Kusamori, K., Nishikawa, M., Itakura, S., Chen, J., Huang, X., Ouyang, D., Riester, O., Deigner, H.-P., Lai, H., Pedraz, J. L., Ramalingam, M., & Cai, Y. (2024). Nano-drug delivery system for the treatment of multidrug-resistant breast cancer: Current status and future perspectives. *Biomedicine & Pharmacotherapy*, *179*, 117327. https://doi.org/10.1016/j.biopha.2024.117327

Gavas, S., Quazi, S., & Karpiński, T. M. (2021). Nanoparticles for Cancer Therapy: Current Progress and Challenges. *Nanoscale Research Letters*, *16*(1), 173. https://doi.org/10.1186/s11671-021-03628-6

Giaquinto, A. N., Sung, H., Miller, K. D., Kramer, J. L., Newman, L. A., Minihan, A., Jemal, A., & Siegel, R. L. (2022). Breast Cancer Statistics, 2022. *CA: A Cancer Journal for Clinicians*, *72*(6), 524–541. https://doi.org/10.3322/caac.21754

Hu, X., Zhang, Y., Ding, T., Liu, J., & Zhao, H. (2020). Multifunctional Gold Nanoparticles: A Novel Nanomaterial for Various Medical Applications and Biological Activities. *Frontiers in Bioengineering and Biotechnology*, *8*, 990. https://doi.org/10.3389/fbioe.2020.00990

Huang, L., Huang, X.-H., Yang, X., Hu, J.-Q., Zhu, Y.-Z., Yan, P.-Y., & Xie, Y. (2024). Novel nano-drug delivery system for natural products and their application. *Pharmacological Research*, *201*, 107100. https://doi.org/10.1016/j.phrs.2024.107100

Jain, V., Kumar, H., Anod, H. V., Chand, P., Gupta, N. V., Dey, S., & Kesharwani, S. S. (2020). A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer. *Journal of Controlled Release*, *326*, 628–647. https://doi.org/10.1016/j.jconrel.2020.07.003

Janib, S. M., Moses, A. S., & MacKay, J. A. (2010). Imaging and drug delivery using theranostic nanoparticles. *Advanced Drug Delivery Reviews*, *62*(11), 1052–1063. https://doi.org/10.1016/j.addr.2010.08.004

Jayaswal, N., Srivastava, S., Kumar, S., Belagodu Sridhar, S., Khalid, A., Najmi, A., Zoghebi, K., Alhazmi, H. A., Mohan, S., & Tambuwala, M. M. (2024). Precision arrows: Navigating breast cancer with nanotechnology siRNA. *International Journal of Pharmaceutics*, *662*, 124403. https://doi.org/10.1016/j.ijpharm.2024.124403

Jha, R., Singh, A., Sharma, P. K., & Fuloria, N. K. (2020). Smart carbon nanotubes for drug delivery system: A comprehensive study. *Journal of Drug Delivery Science and Technology*, *58*, 101811. https://doi.org/10.1016/j.jddst.2020.101811

Jia, Y., Yao, Y., Fan, L., Huang, Q., Wei, G., Shen, P., Sun, J., Zhu, G., Sun, Z., Zhu, C., & Han, X. (2024). Tumor microenvironment responsive nano-herb and CRISPR delivery system for synergistic chemotherapy and immunotherapy. *Journal of Nanobiotechnology*, *22*(1), 346. https://doi.org/10.1186/s12951-024-02571-9

Jiang, L., Li, X., & Lu, Y. S. (2023). Nano-Based Drug Delivery System in Breast Cancer Treatment. *Nano*, *18*(07), 2330003. https://doi.org/10.1142/S1793292023300037

Jiang, Y., Jiang, Z., Wang, M., & Ma, L. (2022). Current understandings and clinical translation of nanomedicines for breast cancer therapy. *Advanced Drug Delivery Reviews*, *180*, 114034. https://doi.org/10.1016/j.addr.2021.114034

Jiang, Y., Li, W., Wang, Z., & Lu, J. (2023). Lipid-Based Nanotechnology: Liposome. *Pharmaceutics*, *16*(1), 34. https://doi.org/10.3390/pharmaceutics16010034

Karahmet Sher, E., Alebić, M., Marković Boras, M., Boškailo, E., Karahmet Farhat, E., Karahmet, A., Pavlović, B., Sher, F., & Lekić, L. (2024). Nanotechnology in medicine revolutionizing drug delivery for cancer and viral infection treatments. *International Journal of Pharmaceutics*, *660*, 124345. https://doi.org/10.1016/j.ijpharm.2024.124345

Kaushik, N., Borkar, S. B., Nandanwar, S. K., Panda, P. K., Choi, E. H., & Kaushik, N. K. (2022). Nanocarrier cancer therapeutics with functional stimuli-responsive mechanisms. *Journal of Nanobiotechnology*, *20*(1), 152. https://doi.org/10.1186/s12951-022-01364-2

Kemp, J. A., & Kwon, Y. J. (2021). Cancer nanotechnology: Current status and perspectives. *Nano Convergence*, *8*(1), 34. https://doi.org/10.1186/s40580-021-00282-7

Kumari, A., Singla, R., Guliani, A., & Yadav, S. K. (2014). Nanoencapsulation for drug delivery. *EXCLI Journal*, *13*, 265–286.

Lan, H., Jamil, M., Ke, G., & Dong, N. (2023). The role of nanoparticles and nanomaterials in cancer diagnosis and treatment: A comprehensive review. *American Journal of Cancer Research*, *13*(12), 5751–5784.

Lei, L., Chen, R., Fan, L., Zheng, W., & Wang, X. (2022). Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with conventional taxanes in women with breast cancer: A systematic review and meta-analysis. *Annals of Palliative Medicine*, *11*(7), 2382–2394. https://doi.org/10.21037/apm-22-690

Li, L., Yang, W.-W., & Xu, D.-G. (2019). Stimuli-responsive nanoscale drug delivery systems for cancer therapy. *Journal of Drug Targeting*, *27*(4), 423–433. https://doi.org/10.1080/1061186X.2018.1519029

Liu, J., Li, S., Wang, J., Li, N., Zhou, J., & Chen, H. (2023). Application of Nano Drug Delivery System (NDDS) in Cancer Therapy: APerspective. *Recent Patents on Anti-Cancer Drug Discovery*, *18*(2), 125–132. https://doi.org/10.2174/1574892817666220713150521

Loibl, S., André, F., Bachelot, T., Barrios, C. H., Bergh, J., Burstein, H. J., Cardoso, M. J., Carey, L. A., Dawood, S., Del Mastro, L., Denkert, C., Fallenberg, E. M., Francis, P. A., Gamal-Eldin, H., Gelmon, K., Geyer, C. E., Gnant, M., Guarneri, V., Gupta, S., … Harbeck, N. (2024). Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Annals of Oncology*, *35*(2), 159–182. https://doi.org/10.1016/j.annonc.2023.11.016

Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021). Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review. *Cancers*, *13*(17), 4287. https://doi.org/10.3390/cancers13174287

Luo, Y., Sun, M., Tan, L., Li, T., & Min, L. (2023). Nano-Based Drug Delivery Systems: Potential Developments in the Therapy of Metastatic Osteosarcoma—A Narrative Review. *Pharmaceutics*, *15*(12), 2717. https://doi.org/10.3390/pharmaceutics15122717

Makadia, H. K., & Siegel, S. J. (2011). Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. *Polymers*, *3*(3), 1377–1397. https://doi.org/10.3390/polym3031377

Malik, J. A., Ansari, J. A., Ahmed, S., Khan, A., Ahemad, N., & Anwar, S. (2023a). Nano-drug Delivery System: A Promising Approach Against Breast Cancer. *Therapeutic Delivery*, *14*(5), 357–381. https://doi.org/10.4155/tde-2023-0020

Malik, J. A., Ansari, J. A., Ahmed, S., Khan, A., Ahemad, N., & Anwar, S. (2023b). Nano-drug Delivery System: A Promising Approach Against Breast Cancer. *Therapeutic Delivery*, *14*(5), 357–381. https://doi.org/10.4155/tde-2023-0020

Mehrotra, R., & Yadav, K. (2022). Breast cancer in India: Present scenario and the challenges ahead. *World Journal of Clinical Oncology*, *13*(3), 209–218. https://doi.org/10.5306/wjco.v13.i3.209

Mi, P. (2020). Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics. *Theranostics*, *10*(10), 4557–4588. https://doi.org/10.7150/thno.38069

Mirza, Z., & Karim, S. (2021). Nanoparticles-based drug delivery and gene therapy for breast cancer: Recent advancements and future challenges. *Seminars in Cancer Biology*, *69*, 226–237. https://doi.org/10.1016/j.semcancer.2019.10.020

Mittal, P., Saharan, A., Verma, R., Altalbawy, F. M. A., Alfaidi, M. A., Batiha, G. E.-S., Akter, W., Gautam, R. K., Uddin, Md. S., & Rahman, Md. S. (2021). Dendrimers: A New Race of Pharmaceutical Nanocarriers. *BioMed Research International*, *2021*, 1–11. https://doi.org/10.1155/2021/8844030

Mukherjee, D., & Raikwar, S. (2024). Recent Update on Nanocarrier(s) as the Targeted Therapy for Breast Cancer. *AAPS PharmSciTech*, *25*(6), 153. https://doi.org/10.1208/s12249-024-02867-x

Nie, D., Guo, T., Yue, M., Li, W., Zong, X., Zhu, Y., Huang, J., & Lin, M. (2022). Research Progress on Nanoparticles-Based CRISPR/Cas9 System for Targeted Therapy of Tumors. *Biomolecules*, *12*(9), 1239. https://doi.org/10.3390/biom12091239

Nsairat, H., Khater, D., Sayed, U., Odeh, F., Al Bawab, A., & Alshaer, W. (2022). Liposomes: Structure, composition, types, and clinical applications. *Heliyon*, *8*(5), e09394. https://doi.org/10.1016/j.heliyon.2022.e09394

Núñez, C., Capelo, J. L., Igrejas, G., Alfonso, A., Botana, L. M., & Lodeiro, C. (2016). An overview of the effective combination therapies for the treatment of breast cancer. *Biomaterials*, *97*, 34–50. https://doi.org/10.1016/j.biomaterials.2016.04.027

Oehler, J. B., Rajapaksha, W., & Albrecht, H. (2024). Emerging Applications of Nanoparticles in the Diagnosis and Treatment of Breast Cancer. *Journal of Personalized Medicine*, *14*(7), 723. https://doi.org/10.3390/jpm14070723

Oshiro-Júnior, J. A., Rodero, C., Hanck-Silva, G., Sato, M. R., Alves, R. C., Eloy, J. O., & Chorilli, M. (2020). Stimuli-responsive Drug Delivery Nanocarriers in the Treatment of Breast Cancer. *Current Medicinal Chemistry*, *27*(15), 2494–2513. https://doi.org/10.2174/0929867325666181009120610

Padayachee, J., & Singh, M. (2020). Therapeutic applications of CRISPR/Cas9 in breast cancer and delivery potential of gold nanomaterials. *Nanobiomedicine*, *7*, 1849543520983196. https://doi.org/10.1177/1849543520983196

Pandey, H., Rani, R., Agarwal, V., Sam Higginbottom Institute of Agriculture Technology & Sciences, India, & Motilal Nehru National Institute of Technology, India. (2016). Liposome and Their Applications in Cancer Therapy. *Brazilian Archives of Biology and Technology*, *59*(0). https://doi.org/10.1590/1678-4324-2016150477

Paris, J. L., Baeza, A., & Vallet-Regí, M. (2019). Overcoming the stability, toxicity, and biodegradation challenges of tumor stimuli-responsive inorganic nanoparticles for delivery of cancer therapeutics. *Expert Opinion on Drug Delivery*, *16*(10), 1095–1112. https://doi.org/10.1080/17425247.2019.1662786

Patel, P., Vedarethinam, V., Korsah, M. A., Danquah, M. K., & Jeevanandam, J. (2024). Exploring the Potential of Nanoparticles in the Treatment of Breast Cancer: Current Applications and Future Directions. *Applied Sciences*, *14*(5), 1809. https://doi.org/10.3390/app14051809

Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., Habtemariam, S., & Shin, H.-S. (2018). Nano based drug delivery systems: Recent developments and future prospects. *Journal of Nanobiotechnology*, *16*(1), 71. https://doi.org/10.1186/s12951-018-0392-8

Prajapati, A., Rangra, S., Patil, R., Desai, N., Jyothi, V. G. S. S., Salave, S., Amate, P., Benival, D., & Kommineni, N. (2024). Receptor-Targeted Nanomedicine for Cancer Therapy. *Receptors*, *3*(3), 323–361. https://doi.org/10.3390/receptors3030016

Priyadarshni, N., Singh, R., & Mishra, M. K. (2024). Nanodiamonds: Next generation nano-theranostics for cancer therapy. *Cancer Letters*, *587*, 216710. https://doi.org/10.1016/j.canlet.2024.216710

Rahim, M. A., Jan, N., Khan, S., Shah, H., Madni, A., Khan, A., Jabar, A., Khan, S., Elhissi, A., Hussain, Z., Aziz, H. C., Sohail, M., Khan, M., & Thu, H. E. (2021). Recent Advancements in Stimuli Responsive Drug Delivery Platforms for Active and Passive Cancer Targeting. *Cancers*, *13*(4), 670. https://doi.org/10.3390/cancers13040670

Ranji, P., Heydari, Z., & Alizadeh, A. (2015). Nanobiotechnological Approaches to Overcome Drug Resistance in Breast Cancer. *Current Cancer Drug Targets*, *15*(7), 544–562. https://doi.org/10.2174/1568009615666150706102842

Rashidi, N., Davidson, M., Apostolopoulos, V., & Nurgali, K. (2024). Nanoparticles in cancer diagnosis and treatment: Progress, challenges, and opportunities. *Journal of Drug Delivery Science and Technology*, *95*, 105599. https://doi.org/10.1016/j.jddst.2024.105599

Rathinavel, S., Priyadharshini, K., & Panda, D. (2021). A review on carbon nanotube: An overview of synthesis, properties, functionalization, characterization, and the application. *Materials Science and Engineering: B*, *268*, 115095. https://doi.org/10.1016/j.mseb.2021.115095

Reddy Baddam, S., Ganta, S., Nalla, S., Banoth, C., Vudari, B., Akkiraju, P. C., Srinivas, E., & Tade, R. S. (2024). Polymeric nanomaterials-based theranostic platforms for triple-negative breast cancer (TNBC) treatment. *International Journal of Pharmaceutics*, *660*, 124346. https://doi.org/10.1016/j.ijpharm.2024.124346

Riley, R. S., & Day, E. S. (2017). Gold nanoparticle-mediated photothermal therapy: Applications and opportunities for multimodal cancer treatment. *WIREs Nanomedicine and Nanobiotechnology*, *9*(4), e1449. https://doi.org/10.1002/wnan.1449

Sakore, P., Bhattacharya, S., Belemkar, S., Prajapati, B. G., & Elossaily, G. M. (2024). The theranostic potential of green nanotechnology-enabled gold nanoparticles in cancer: A paradigm shift on diagnosis and treatment approaches. *Results in Chemistry*, *7*, 101264. https://doi.org/10.1016/j.rechem.2023.101264

Salahpour Anarjan, F. (2019). Active targeting drug delivery nanocarriers: Ligands. *Nano-Structures & Nano-Objects*, *19*, 100370. https://doi.org/10.1016/j.nanoso.2019.100370

Santos, A., Veiga, F., & Figueiras, A. (2019). Dendrimers as Pharmaceutical Excipients: Synthesis, Properties, Toxicity and Biomedical Applications. *Materials*, *13*(1), 65. https://doi.org/10.3390/ma13010065

Shafei, A., El-Bakly, W., Sobhy, A., Wagdy, O., Reda, A., Aboelenin, O., Marzouk, A., El Habak, K., Mostafa, R., Ali, M. A., & Ellithy, M. (2017). A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer. *Biomedicine & Pharmacotherapy*, *95*, 1209–1218. https://doi.org/10.1016/j.biopha.2017.09.059

Shar, A., Shar, A., & Joung, D. (2023). Carbon nanotube nanocomposite scaffolds: Advances in fabrication and applications for tissue regeneration and cancer therapy. *Frontiers in Bioengineering and Biotechnology*, *11*, 1299166. https://doi.org/10.3389/fbioe.2023.1299166

Sharma, G. (2024). Biogenic carbon nanostructured materials for detection of cancer and medical applications: A mini review. *Hybrid Advances*, *5*, 100166. https://doi.org/10.1016/j.hybadv.2024.100166

Shi, P., Cheng, Z., Zhao, K., Chen, Y., Zhang, A., Gan, W., & Zhang, Y. (2023). Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics. *Journal of Nanobiotechnology*, *21*(1), 103. https://doi.org/10.1186/s12951-023-01826-1

Sibuyi, N. R. S., Moabelo, K. L., Fadaka, A. O., Meyer, S., Onani, M. O., Madiehe, A. M., & Meyer, M. (2021). Multifunctional Gold Nanoparticles for Improved Diagnostic and Therapeutic Applications: A Review. *Nanoscale Research Letters*, *16*(1), 174. https://doi.org/10.1186/s11671-021-03632-w

Sim, S., & Wong, N. (2021). Nanotechnology and its use in imaging and drug delivery (Review). *Biomedical Reports*, *14*(5), 42. https://doi.org/10.3892/br.2021.1418

Sneider, A., VanDyke, D., Paliwal, S., & Rai, P. (2017). Remotely Triggered Nano-Theranostics For Cancer Applications. *Nanotheranostics*, *1*(1), 1–22. https://doi.org/10.7150/ntno.17109

Song, G., Darr, D. B., Santos, C. M., Ross, M., Valdivia, A., Jordan, J. L., Midkiff, B. R., Cohen, S., Nikolaishvili-Feinberg, N., Miller, C. R., Tarrant, T. K., Rogers, A. B., Dudley, A. C., Perou, C. M., & Zamboni, W. C. (2014). Effects of Tumor Microenvironment Heterogeneity on Nanoparticle Disposition and Efficacy in Breast Cancer Tumor Models. *Clinical Cancer Research*, *20*(23), 6083–6095. https://doi.org/10.1158/1078-0432.CCR-14-0493

Song, Z., Tao, Y., Liu, Y., & Li, J. (2024). Advances in delivery systems for CRISPR/Cas-mediated cancer treatment: A focus on viral vectors and extracellular vesicles. *Frontiers in Immunology*, *15*, 1444437. https://doi.org/10.3389/fimmu.2024.1444437

Spada, A., Emami, J., Tuszynski, J. A., & Lavasanifar, A. (2021). The Uniqueness of Albumin as a Carrier in Nanodrug Delivery. *Molecular Pharmaceutics*, *18*(5), 1862–1894. https://doi.org/10.1021/acs.molpharmaceut.1c00046

Stylianopoulos, T. (2013). EPR-effect: Utilizing size-dependent Nanoparticle Delivery to Solid Tumors. *Therapeutic Delivery*, *4*(4), 421–423. https://doi.org/10.4155/tde.13.8

Subhan, M. A., Yalamarty, S. S. K., Filipczak, N., Parveen, F., & Torchilin, V. P. (2021). Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment. *Journal of Personalized Medicine*, *11*(6), 571. https://doi.org/10.3390/jpm11060571

Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023). Smart nanoparticles for cancer therapy. *Signal Transduction and Targeted Therapy*, *8*(1), 418. https://doi.org/10.1038/s41392-023-01642-x

Sun, R., Chen, Y., Pei, Y., Wang, W., Zhu, Z., Zheng, Z., Yang, L., & Sun, L. (2024). The drug release of PLGA-based nanoparticles and their application in treatment of gastrointestinal cancers. *Heliyon*, *10*(18), e38165. https://doi.org/10.1016/j.heliyon.2024.e38165

Sun, S., Wang, Y., Gao, X., Wang, H., Zhang, L., Wang, N., Li, C., & Xiong, S. (2023). Current perspectives and trends in nanoparticle drug delivery systems in breast cancer: Bibliometric analysis and review. *Frontiers in Bioengineering and Biotechnology*, *11*, 1253048. https://doi.org/10.3389/fbioe.2023.1253048

Sun, X., Liu, K., Lu, S., He, W., & Du, Z. (2022). Targeted Therapy and Immunotherapy for Heterogeneous Breast Cancer. *Cancers*, *14*(21), 5456. https://doi.org/10.3390/cancers14215456

Surya, C., Lakshminarayana, A. B. V., Ramesh, S. H., Kunjiappan, S., Theivendren, P., Santhana Krishna Kumar, A., Ammunje, D. N., & Pavadai, P. (2024). Advancements in breast cancer therapy: The promise of copper nanoparticles. *Journal of Trace Elements in Medicine and Biology*, *86*, 127526. https://doi.org/10.1016/j.jtemb.2024.127526

Taher, M., Susanti, D., Haris, M. S., Rushdan, A. A., Widodo, R. T., Syukri, Y., & Khotib, J. (2023). PEGylated liposomes enhance the effect of cytotoxic drug: A review. *Heliyon*, *9*(3), e13823. https://doi.org/10.1016/j.heliyon.2023.e13823

Tang, X., Loc, W. S., Dong, C., Matters, G. L., Butler, P. J., Kester, M., Meyers, C., Jiang, Y., & Adair, J. H. (2017). The Use of Nanoparticulates to Treat Breast Cancer. *Nanomedicine*, *12*(19), 2367–2388. https://doi.org/10.2217/nnm-2017-0202

Tenchov, R., Bird, R., Curtze, A. E., & Zhou, Q. (2021). Lipid Nanoparticles─From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. *ACS Nano*, *15*(11), 16982–17015. https://doi.org/10.1021/acsnano.1c04996

Thomas, R. G., Surendran, S. P., & Jeong, Y. Y. (2020). Tumor Microenvironment-Stimuli Responsive Nanoparticles for Anticancer Therapy. *Frontiers in Molecular Biosciences*, *7*, 610533. https://doi.org/10.3389/fmolb.2020.610533

Vines, J. B., Yoon, J.-H., Ryu, N.-E., Lim, D.-J., & Park, H. (2019). Gold Nanoparticles for Photothermal Cancer Therapy. *Frontiers in Chemistry*, *7*, 167. https://doi.org/10.3389/fchem.2019.00167

Wasilewski, T., Kamysz, W., & Gębicki, J. (2024). AI-Assisted Detection of Biomarkers by Sensors and Biosensors for Early Diagnosis and Monitoring. *Biosensors*, *14*(7), 356. https://doi.org/10.3390/bios14070356

Wu, J. (2021). The Enhanced Permeability and Retention (EPR) Effect: The Significance of the Concept and Methods to Enhance Its Application. *Journal of Personalized Medicine*, *11*(8), 771. https://doi.org/10.3390/jpm11080771

Xin, H., & Naficy, S. (2022). Drug Delivery Based on Stimuli-Responsive Injectable Hydrogels for Breast Cancer Therapy: A Review. *Gels*, *8*(1), 45. https://doi.org/10.3390/gels8010045

Yan, S., Na, J., Liu, X., & Wu, P. (2024). Different Targeting Ligands-Mediated Drug Delivery Systems for Tumor Therapy. *Pharmaceutics*, *16*(2), 248. https://doi.org/10.3390/pharmaceutics16020248

Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., Wu, S., Deng, Y., Zhang, J., & Shao, A. (2020). Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance. *Frontiers in Molecular Biosciences*, *7*, 193. https://doi.org/10.3389/fmolb.2020.00193

Yap, K. M., Sekar, M., Fuloria, S., Wu, Y. S., Gan, S. H., Mat Rani, N. N. I., Subramaniyan, V., Kokare, C., Lum, P. T., Begum, M. Y., Mani, S., Meenakshi, D. U., Sathasivam, K. V., & Fuloria, N. K. (2021). Drug Delivery of Natural Products Through Nanocarriers for Effective Breast Cancer Therapy: A Comprehensive Review of Literature. *International Journal of Nanomedicine*, *Volume 16*, 7891–7941. https://doi.org/10.2147/IJN.S328135

Yu, J., Mu, Q., Fung, M., Xu, X., Zhu, L., & Ho, R. J. Y. (2022). Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response. *Pharmacology & Therapeutics*, *236*, 108108. https://doi.org/10.1016/j.pharmthera.2022.108108

Zandieh, M. A., Farahani, M. H., Daryab, M., Motahari, A., Gholami, S., Salmani, F., Karimi, F., Samaei, S. S., Rezaee, A., Rahmanian, P., Khorrami, R., Salimimoghadam, S., Nabavi, N., Zou, R., Sethi, G., Rashidi, M., & Hushmandi, K. (2023). Stimuli-responsive (nano)architectures for phytochemical delivery in cancer therapy. *Biomedicine & Pharmacotherapy*, *166*, 115283. https://doi.org/10.1016/j.biopha.2023.115283

Zhang, J., Li, X., & Huang, L. (2014). Non-viral nanocarriers for siRNA delivery in breast cancer. *Journal of Controlled Release*, *190*, 440–450. https://doi.org/10.1016/j.jconrel.2014.05.037

Zou, T., Lu, W., Mezhuev, Y., Lan, M., Li, L., Liu, F., Cai, T., Wu, X., & Cai, Y. (2021). A review of nanoparticle drug delivery systems responsive to endogenous breast cancer microenvironment. *European Journal of Pharmaceutics and Biopharmaceutics*, *166*, 30–43. https://doi.org/10.1016/j.ejpb.2021.05.029